

## FORM 51-102F3

### MATERIAL CHANGE REPORT UNDER NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company**

CB2 Insights Inc. (the “Company”)  
5045 Orbitor Drive, Building 11, Unit 300  
Mississauga, Ontario, L4W 4Y4

2. **Date of Material Change**

July 31, 2019

3. **News Release**

A news release with respect to the material change referred to in this report was disseminated through GlobalNewswire on July 31, 2019 and filed on the system for electronic document analysis and retrieval (SEDAR).

4. **Summary of Material Change**

CB2 Insights Adds Former Johnson & Johnson Executive as Director

5. **Full Description of Material Change**

“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has appointed former Johnson & Johnson executive Peter Cummins as a Director to its Board, increasing the size of its Board of Directors to seven (7) members.

“The high interest and development potential that exists between medical cannabis and traditional healthcare is enormous”, said Mr. Cummins. “CB2 Insights is the bridge between these two industries through clinically-driven observational data which is key to the development of cannabis-based medicine by pharmaceutical companies across the globe. I am excited about the Company’s prospects and look forward to assist and guide in the execution of their strategy to provide best-in-class medical cannabis research support to the healthcare industry.”

Mr. Cummins adds a depth of experience to CB2 Insights from the traditional healthcare sector. He spent over two decades with Johnson & Johnson, including executive leadership roles overseeing research and development, product development, external innovation, regulatory affairs and hospital pharmacy across Canada, the US, Europe and other regions. Prior to Johnson & Johnson, Mr. Cummins served in Regulatory and Scientific Affairs at Procter & Gamble, and he was the Director of Pharmacy at Cambridge Memorial Hospital. He holds a BSc in Pharmacy from the University of Toronto and an MBA from Wilfred Laurier University.

“Peter has extensive experience in traditional pharmaceutical research and development. He brings a crucial understanding and network to CB2 Insights that will undoubtedly help to unlock the value of the Company’s data assets moving forward,” said David Danziger, Chairman of the Board, CB2 Insights.

This new appointment increases the number of board members from 6 to 7, with a majority of independent Directors with experience in corporate finance, taxation, auditing, capital markets, technology, data analytics, medical cannabis, healthcare and pharmaceuticals.

6. **Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

7. **Omitted Information**

Not applicable.

8. **Executive Officer**

For further information, contact Prad Sekar, CEO of CB2 Insights Inc. at 1-855-874-4999.

9. **Date of Report**

July 31, 2019